Condition: Colorectal Cancer Metastatic · Sponsor: National Cancer Institute, Naples
The investigators hypothesize that the epigenetic agent valproic acid improve the activity of anti-EGFR agents, prevent and revert the emergence of EGFR resistance, in a rechallenge setting. Correlative mechanistic studies on tissue and blood samples, liquid biopsies, could identify potential biomarkers of efficacy and help understanding the evolutionary dynamics of tumors in response to therapy thus optimizing the treatment approach with a personalized anti- EGFR treatment strategy.
This description comes directly from the study's public registry record.
Antonio Avallone, MD · 08117770357 · a.avallone@istitutotumori.na.it
Alfredo Budillon, MD · 08117770583 · a.budillon@istitutotumori.na.it
Always discuss trial participation with your own doctor first.
| AORN Sant'Anna e San Sebastiano | Caserta, CE, Italy | Recruiting |
| Università degli studi della Campania Luigi Vanvitelli | Naples, Italia, Italy | Recruiting |
| AORN San Giuseppe Moscati Avellino | Avellino, Italy, Italy | Active Not Recruiting |
| Azienda Sanitaria Universitaria Friuli Centrale | Udine, Italy, Italy | Not Yet Recruiting |
| Pia Fondazione Di Culto E Religione Card G Panico | Tricase, Lecce, Italy | Not Yet Recruiting |
| Ospedale Civile San Giovanni di Dio | Frattamaggiore, Napoli, Italy | Not Yet Recruiting |
| Istituto Nazionale Tumori IRCCS Fondazione G. Pascale | Naples, Napoli, Italy | Recruiting |
| Presidio Ospedaliero "Santa Maria delle Grazie" | Pozzuoli, PZ, Italy | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06714357